Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 27;13:3688. doi: 10.1038/s41467-022-31229-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A CD26^hiCD161+ CD8+ T cells contain Tc17 cells and express higher CD6 as illustrated by original plots and overlay histograms of live CD8+ and CD26^hiCD161+ CD8+ T cells from PBMC and intestinal tissue of a CD patient analyzed for IL-17A and CD6. B Reduction in CD26^hiCD161+ CD8+ T cells in presence of anti-CD6 (Itolizumab) treatment during culture of PBMCs overnight (o/n), or for three or seven days (d3, d7) (plots gated on CD8+ T cells). C Cell numbers in anti-CD6 vs. control-treated assays (n = 4 for each condition). D Percentage of CD26^hiCD161+ CD8+ T cells in presence of RPMI, Itolizumab (n = 8) or UMCD6 (n = 5). E Percentage of IL-17A+ CD8+ T cells in presence of RPMI, Itolizumab (n = 14) or UMCD6 (n = 13). F Proportion of IFN-γ and TNF mono- and coproduction by IL-17A+ CD8+ CD3+ T cells in presence of RPMI or Itolizumab (n = 8). G IL-17A production of CD8+ T cells from intestinal biopsies after five-hour stimulation in presence of RPMI or UMCD6. Depicted are samples from a CD patient with clinical and endoscopic remission and a patient with clinical and endoscopic activity. D, E Data after 5 h PMA/Ionomycin stimulation; (B–E) assays performed on HD samples. Data in (C) and (F) are presented as mean +/− SEM. Statistical tests used were two-sided. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.